Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL

September 7th 2023

Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.

Early Cytogenetic or Molecular Landmark Response to Ponatinib Predicts Outcomes in CP-CML

September 7th 2023

Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.

FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

September 7th 2023

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML

September 7th 2023

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.

Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL

September 6th 2023

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Bispecific Antibodies May Revolutionize the Management of B-Cell Lymphoma

September 6th 2023

The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

FDA Approval Sought for Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

September 6th 2023

The FDA has accepted a biologics license application seeking the approval of crovalimab for use in patients with paroxysmal nocturnal hemoglobinuria.

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5th 2023

The National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received at least 1 therapy.

PhALLCON Trial: Safety and Efficacy of Ponatinib in Philadelphia-positive ALL

September 5th 2023

Expert hematologist-oncologists consider how the PhALLCON trial elucidates the safety of ponatinib in Ph+ ALL, highlighting comparable toxicity rates and favorable efficacy endpoints.

Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study Highlights

September 5th 2023

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment.

Challenges with Early Diagnosis of GVHD

September 4th 2023

Mahasweta Gooptu, MD shares insights on the early identification and diagnosis of chronic GVHD.

Chronic GVHD Incidence and Risk Factors

September 4th 2023

Dr Gooptu discusses the incidence of chronic GVHD and ruminates on how a patient’s medical history may impact their chronic GVHD risk.

Role of BTK Inhibitors in Relapsed/Refractory Follicular Lymphoma

September 1st 2023

A brief review of BTK inhibitor therapy and its potential role within the relapsed/refractory follicular lymphoma treatment landscape.

Patient Scenario 1: An 83 -Year-Old With Relapsed/Refractory FL

September 1st 2023

Centering discussion on a patient scenario of relapsed/refractory follicular lymphoma, key opinion leaders consider how they would select best available therapy in this setting.

Dr Shah on the Investigation of Split-Dose R-CHOP in DLBCL

August 31st 2023

Nirav N. Shah, MD, discusses primary outcomes from a phase 2 trial investigating split-dose R-CHOP in older patients with diffuse large B-cell lymphoma.

Acute Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Following the ASCO 2023 and EHA 2023 Annual Meetings, experts discuss important updates in acute myeloid leukemia.

Acute Lymphoblastic Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Shared insight from key opinion leaders on clinical trial data in acute lymphoblastic leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

Chronic Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Expert perspectives on key data in chronic myeloid leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

FDA Grants Orphan Drug Designation to Bexmarilimab for AML

August 29th 2023

The FDA has granted an orphan drug designation to bexmarilimab for the treatment of patients with acute myeloid leukemia.

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29th 2023

The addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy.